5 funding opportunities found in this category. 

Request for Proposals: Creative Computational Approaches to Accelerate Drug Discovery for the Treatment and Prevention of Dementia
Alzheimer’s Drug Discovery Foundation
All Regions
08/22/2013
$150,000

Request for Proposals: Creative Computational Approaches to Accelerate Drug Discovery for the Treatment and Prevention of Dementia

Current methods of drug discovery have had limited success at predicting clinical efficacy of investigational therapies in patients with Alzheimer’s disease and other age-related dementias.

Computational modeling, systems biology and pharmacology, and translational bioinformatics represent
a tremendous yet relatively under-developed opportunity to accelerate and improve this process particularly for dementias.

The Alzheimer’s Drug Discovery Foundation (ADDF) program on Aging & Alzheimer’s Disease Prevention is requesting proposals for innovative computational approaches to map disease and predict the efficacy of drugs to treat and prevent dementia. A variety of approaches and outcomes will be considered.

Priority will be given to interdisciplinary teams composed of computational and biology/disease experts, and to proposals that use and perhaps develop open-access databases of biological and clinical data.

The winning submission(s) will present the most scientifically compelling, novel, and viable program to accelerate drug discovery.

Funding Opportunity #1.

Novel computational approaches to modeling drug efficacy on a key therapeutic target for Alzheimer’s disease.
Quantitative systems pharmacology and other network modeling approaches are of interest, as well as translational bioinformatics approaches to rational drug repurposing and rational combinatorial therapies.

Priority will be given to targets other than beta-amyloid and acetylcholinesterase, including but not limited to neuroinflammation, mitochondrial function, insulin sensitivity, cholesterol and ApoE, and the neurovascular
unit.

Some applications may benefit from the use of the databases including but not limited to:

- The Gene Expression Omnibus (GEO) open-access database of genomics data and ProfileChaser, a related web server

-Life Sciences databases.

Funding Opportunity #2.

Novel computational approaches to model disease risk and progression based on risk factors. Research increasingly indicates that Alzheimer’s is a multi-factorial disease that can develop along different trajectories with multiple risk factors such as genotype, comorbidities, dietary and environmental factors.

Some applications may benefit from the use of open-access databases of epidemiological data
including but not limited to:

- The National Alzheimer’s Coordinating Center (NACC) (http://www.alz.washington.edu),

-The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (http://adni.loni.ucla.edu/data-samples/access
-data/),

- The C-Path online Data Repository (CODR) for Alzheimer’s Disease (http://www.c-path.org/CAMDcodr.cfm).

Mechanism(s) of support:

Up to $150,000 in funding is available for each grant for one-year duration, with the possibility of follow-
on funding for computational or experimental research.

Review Process:

The deadline date for applications is September 5, 2013.

Submission of a Letter of Intent (LOI) is required prior to August 22, 2013.

Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee. The award winner (s) will be publicly announced in Spring 2014.

Application Procedure:

All letters of intent and applications must be submitted electronically at www.alzdiscovery.org. Detailed application instructions are available on the website.

Physician Researcher, Neuroscientist, Pharmacologist
Request for Proposals: Accelerating Drug Discovery for Frontotemporal Dementias
Alzheimer’s Drug Discovery Foundation/Association for Frontotemporal Degeneration
All Regions
08/22/2013
$150,000

Request for Proposals: Accelerating Drug Discovery for Frontotemporal Dementias

Research investigating the pathologic mechanisms of neurodegeneration in frontotemporal dementia (FTD) and related disorders is advancing, creating new potential targets for drug discovery. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for  frontotemporal Degeneration (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this Request for Proposals (RFP).

Priority areas for this program include:

• Development of biomarkers to accelerate drug development and early diagnosis

• Innovative pilot clinical trials

• Target validation studies

• Development and testing of novel high throughput screening assays

• Medicinal chemistry on lead compounds

• Identification and in vitro testing of potentially disease modifying lead compounds

• ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds

• Testing of lead compounds in a relevant animal model for preclinical proof of concept

Please note: this funding will not support applications for basic research.

Mechanism (s) of support:

ADDF/AFTD will provide grants for one-year duration (up to $150,000 each) with the possibility of follow-on funding.

Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program
-related investment.

The deadline date for applications is September 5, 2013.

Submission of a Letter of Intent (LOI) is required prior to August 22nd, 2013.

Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee, including
members of AFTD’s Medical Advisory Council.

Applications from biotechnology companies will also be reviewed by ADDF’s external Business Advisory Board.
Award winners will be publicly announced in Spring 2014.

APPLICATION PROCEDURE

All letters of intent and applications must be submitted electronically at www.alzdiscovery.org.

Physician Researcher, Neurologist, Medicinal Chemist, Pharmacologist
Call for Nominations: Gary Neil Prize for Innovation in Drug Development
American Society for Clinical Pharmacology and Therapeutics
All Regions
06/27/2013
$2,500

Call for Nominations: Gary Neil Prize for Innovation in Drug Development

The Gary Neil Prize for Innovation in Drug Development was established in 2004 to honor the memory of Gary Neil, Ph.D. Dr. Neil, a former leader of worldwide Research and Development at Wyeth-Ayerst, was a pioneer in the field of drug development. Dr. Neil was instrumental in creating a highly effective drug development and strategic decision-making structure at Alza through his roles as CEO and President of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals Corporation. Dr. Neil had a significant role as a member of the boards of directors of Pharsight Corporation, Geron Corporation, Calydon and several other biotech companies.

The goal of the Gary Neil Prize for Innovation in Drug Development is to stimulate the application of innovative science to clinical drug development by recognizing outstanding individuals or teams who have been leaders in this area.

Eligibility

Individuals as well as teams who have demonstrated leadership in the application of significant, innovative science to clinical drug development. The award is open to individuals from all clinical pharmacology employment sectors.

Prize and Presentation

The Gary Neil Prize for Innovation in Drug Development will be presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $2,500 honorarium. Travel expenses, hotel expenses and meeting registration will be reimbursed by the Society.

The nomination deadline is Thursday, June 27, 2013.

To submit a nomination, please complete the online nomination form. Please send CVs, letters of support, and other supporting documents to ASCPT at meetings@ascpt.org

Physician Researcher, Pharmacologist
Children's Tumor Foundation Drug Discovery Initiative Award
Children's Tumor Foundation
All Regions
08/31/2013
$50,000

Children's Tumor Foundation Drug Discovery Initiative Award

Drug Discovery Initiative (DDI) Awards fund pilot stage drug testing offering seed grants of $25,000 for in vitro studies and $50,000 for in vivo studies.

Established in 2006, DDI Awards have been one of the Children's Tumor Foundation's most successful programs. Many DDI awardees have successfully secured follow-on funding, and established key relationships with the biotech and pharmaceutical industries.

The next DDI Award deadlines are April 15th & August 31st.

If you have any questions please contact Dan Aiese at daiese@ctf.org.

Physician Researcher, Pharmacologist
International Rett Syndrome Foundation Translational Research Program
International Rett Syndrome Foundation
All Regions
07/01/2013
$600,000

International Rett Syndrome Foundation Translational Research Program

Cycle 2 Letter of Intent due:  July 1, 2013

IRSF announces the availability of HeART (Help Accelerate RTT Therapeutics) and ANGEL (Advanced Neurotherapeutic Grant of Excellence) grant awards to promote the development and testing of therapeutics to treat and reverse Rett syndrome (RTT) and its symptoms. These award mechanisms seek to facilitate the development and testing of novel therapeutics targeting the underlying pathology of the disorder, thereby leading to an amelioration of symptoms or ultimately a pharmacological reversal of RTT. Through these awards, IRSF seeks to foster academic and public-private partnerships and further facilitate drug discovery, development and testing.

IRSF encourages novel research programs that broadly encompass the following areas of unmet need:

Design, synthesis and testing of potential disease modifying therapeutics to treat or reverse RTT

Testing of existing therapeutics both in vitro and in vivo to repurpose their use in RTT

Development and/or validation of in vitro and in vivo models of RTT for therapeutic testing

Development and/or validation of novel biomarkers for objective clinical trials outcome measures

Testing of IND-ready therapeutics in pilot clinical trials

IRSF encourages investigators to utilize the newly available IRSF SMART Library of compounds in their proposed studies.

HeART (Help Accelerate RTT Therapeutics) Grant Award

Goal: To provide seed funding for early stage drug discovery and development efforts.

Funding: The maximum funding level for HeART grant awards is $150,000 for two years.

HeART grant awards are provided for cell-based assay development, early-stage drug discovery and development, early stage medicinal chemistry efforts on high value candidate therapeutics, cell-based screening of candidate therapeutics and follow-on early-stage in vivo testing. Grant applications for exploratory studies towards development of biomarkers or objective clinical outcome measures will also be considered.

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Grant Award

Goal: To provide funding for the later stages of translational research.

Funding: The maximum funding level for ANGEL grant awards is $300,000 per year for up to two years.

Proposals must be comprised of very specific programs focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates. This mechanism requires development of a milestone based research plan, interim reporting on milestones and interaction with IRSF staff prior to and during the award period. The budget and duration of funding are variable and continued funding will be based on satisfactory progress on milestones. Applications are usually solicited, however, unsolicited proposals will be considered. Preliminary inquiries are required to determine IRSF’s level of interest prior to submission of an Expression of Interest (EOI).

Frequency:

Awards will be made in two cycles in 2013.

Please Note: IRSF requires all applicants to use our online submission process.

For application submission inquiries, please contact:

Janice Ascano, Ph.D. Manager of Grants and Research - jascano@rettsyndrome.org | 917-267-4504

For program related inquiries, please contact:

Steve Kaminsky, Ph.D., Chief Science Officer - skaminsky@rettsyndrome.org | 301-961-1559

Physician Researcher, Neurologist